Eptinezumab administered intravenously, subcutaneously, or intramuscularly in healthy subjects and/or patients with migraine: Early development studies
[摘要] Objective: To report the safety, tolerability, and pharmacokinetics/pharmacodynamics (PK/PD) of eptinezumab using intravenous (IV) infusion compared to other routes of administration from two phase 1 trials.
[发布日期] [发布机构]
[效力级别] [学科分类] 兽医学
[关键词] eptinezumab;immunogenicity;intravenous administration;migraine;pharmacodynamics;pharmacokinetics;safety [时效性]
